The PD-1 and PD-L1 Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global PD-1 and PD-L1 Immunotherapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Solid Tumors accounting for % of the PD-1 and PD-L1 Immunotherapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While PD-1 inhibitor segment is altered to a % CAGR between 2022 and 2028.
Global key companies of PD-1 and PD-L1 Immunotherapy include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
PD-1 and PD-L1 Immunotherapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
PD-1 inhibitor
PD-L1 inhibitor
Market segment by Application, can be divided into
Solid Tumors
Blood-related Tumors
Market segment by players, this report covers
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe PD-1 and PD-L1 Immunotherapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of PD-1 and PD-L1 Immunotherapy, with revenue, gross margin and global market share of PD-1 and PD-L1 Immunotherapy from 2019 to 2022.
Chapter 3, the PD-1 and PD-L1 Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and PD-1 and PD-L1 Immunotherapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe PD-1 and PD-L1 Immunotherapy research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Immunotherapy
1.2 Classification of PD-1 and PD-L1 Immunotherapy by Type
1.2.1 Overview: Global PD-1 and PD-L1 Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type in 2021
1.2.3 PD-1 inhibitor
1.2.4 PD-L1 inhibitor
1.3 Global PD-1 and PD-L1 Immunotherapy Market by Application
1.3.1 Overview: Global PD-1 and PD-L1 Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Global PD-1 and PD-L1 Immunotherapy Market Size & Forecast
1.5 Global PD-1 and PD-L1 Immunotherapy Market Size and Forecast by Region
1.5.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global PD-1 and PD-L1 Immunotherapy Market Size by Region, (2017-2022)
1.5.3 North America PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2017-2028)
1.5.4 Europe PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2017-2028)
1.5.6 South America PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 PD-1 and PD-L1 Immunotherapy Market Drivers
1.6.2 PD-1 and PD-L1 Immunotherapy Market Restraints
1.6.3 PD-1 and PD-L1 Immunotherapy Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
2.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 F. Hoffmann-La Roche
2.3.1 F. Hoffmann-La Roche Details
2.3.2 F. Hoffmann-La Roche Major Business
2.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
2.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 F. Hoffmann-La Roche Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
2.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Merck Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
2.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
2.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Roche Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
2.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Jiangsu HengRui Medicine
2.8.1 Jiangsu HengRui Medicine Details
2.8.2 Jiangsu HengRui Medicine Major Business
2.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
2.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Jiangsu HengRui Medicine Recent Developments and Future Plans
2.9 Innovent
2.9.1 Innovent Details
2.9.2 Innovent Major Business
2.9.3 Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
2.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Innovent Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
2.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
2.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 PD-1 and PD-L1 Immunotherapy Players Market Share in 2021
3.2.2 Top 10 PD-1 and PD-L1 Immunotherapy Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 PD-1 and PD-L1 Immunotherapy Players Head Office, Products and Services Provided
3.4 PD-1 and PD-L1 Immunotherapy Mergers & Acquisitions
3.5 PD-1 and PD-L1 Immunotherapy New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Market Share by Type (2017-2022)
4.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Application (2017-2022)
5.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2028)
6.2 North America PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2028)
6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Country
6.3.1 North America PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2028)
6.3.2 United States PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2028)
7.2 Europe PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2028)
7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country
7.3.1 Europe PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2028)
7.3.2 Germany PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
7.3.3 France PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
7.3.4 United Kingdom PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
7.3.5 Russia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
7.3.6 Italy PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2028)
8.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2028)
8.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region
8.3.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Region (2017-2028)
8.3.2 China PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
8.3.3 Japan PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
8.3.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
8.3.5 India PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
8.3.7 Australia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2028)
9.2 South America PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2028)
9.3 South America PD-1 and PD-L1 Immunotherapy Market Size by Country
9.3.1 South America PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2028)
9.3.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
9.3.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2028)
10.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2028)
10.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country
10.3.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2028)
10.3.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
10.3.4 UAE PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global PD-1 and PD-L1 Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global PD-1 and PD-L1 Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market PD-1 and PD-L1 Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Region (2017-2022)
Table 5. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Region (2023-2028)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 9. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 13. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. F. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
Table 15. F. Hoffmann-La Roche Major Business
Table 16. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 17. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Merck Corporate Information, Head Office, and Major Competitors
Table 19. Merck Major Business
Table 20. Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 21. Merck PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Pfizer Corporate Information, Head Office, and Major Competitors
Table 23. Pfizer Major Business
Table 24. Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 25. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Roche Corporate Information, Head Office, and Major Competitors
Table 27. Roche Major Business
Table 28. Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 29. Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Novartis Corporate Information, Head Office, and Major Competitors
Table 31. Novartis Major Business
Table 32. Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 33. Novartis PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Jiangsu HengRui Medicine Corporate Information, Head Office, and Major Competitors
Table 35. Jiangsu HengRui Medicine Major Business
Table 36. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 37. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Innovent Corporate Information, Head Office, and Major Competitors
Table 39. Innovent Major Business
Table 40. Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 41. Innovent PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 43. Eli Lilly Major Business
Table 44. Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 45. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 49. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 51. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 52. Breakdown of PD-1 and PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. PD-1 and PD-L1 Immunotherapy Players Head Office, Products and Services Provided
Table 54. PD-1 and PD-L1 Immunotherapy Mergers & Acquisitions in the Past Five Years
Table 55. PD-1 and PD-L1 Immunotherapy New Entrants and Expansion Plans
Table 56. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Type (2017-2022)
Table 57. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Type (2017-2022)
Table 58. Global PD-1 and PD-L1 Immunotherapy Revenue Forecast by Type (2023-2028)
Table 59. Global PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2022)
Table 60. Global PD-1 and PD-L1 Immunotherapy Revenue Forecast by Application (2023-2028)
Table 61. North America PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 62. North America PD-1 and PD-L1 Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 63. North America PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 64. North America PD-1 and PD-L1 Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 65. North America PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 66. North America PD-1 and PD-L1 Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 67. Europe PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 68. Europe PD-1 and PD-L1 Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 69. Europe PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 70. Europe PD-1 and PD-L1 Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 71. Europe PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 72. Europe PD-1 and PD-L1 Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 73. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 74. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 75. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 76. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 77. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Region (2017-2022) & (USD Million)
Table 78. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue by Region (2023-2028) & (USD Million)
Table 79. South America PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 80. South America PD-1 and PD-L1 Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 81. South America PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 82. South America PD-1 and PD-L1 Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 83. South America PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 84. South America PD-1 and PD-L1 Immunotherapy Revenue by Country (2023-2028) & (USD Million)
Table 85. Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Type (2017-2022) & (USD Million)
Table 86. Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Type (2023-2028) & (USD Million)
Table 87. Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Application (2017-2022) & (USD Million)
Table 88. Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Application (2023-2028) & (USD Million)
Table 89. Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Country (2017-2022) & (USD Million)
Table 90. Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. PD-1 and PD-L1 Immunotherapy Picture
Figure 2. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type in 2021
Figure 3. PD-1 inhibitor
Figure 4. PD-L1 inhibitor
Figure 5. PD-1 and PD-L1 Immunotherapy Revenue Market Share by Application in 2021
Figure 6. Solid Tumors Picture
Figure 7. Blood-related Tumors Picture
Figure 8. Global PD-1 and PD-L1 Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 9. Global PD-1 and PD-L1 Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 11. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Region in 2021
Figure 12. North America PD-1 and PD-L1 Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 13. Europe PD-1 and PD-L1 Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. South America PD-1 and PD-L1 Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. PD-1 and PD-L1 Immunotherapy Market Drivers
Figure 18. PD-1 and PD-L1 Immunotherapy Market Restraints
Figure 19. PD-1 and PD-L1 Immunotherapy Market Trends
Figure 20. AstraZeneca Recent Developments and Future Plans
Figure 21. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 22. F. Hoffmann-La Roche Recent Developments and Future Plans
Figure 23. Merck Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Roche Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Jiangsu HengRui Medicine Recent Developments and Future Plans
Figure 28. Innovent Recent Developments and Future Plans
Figure 29. Eli Lilly Recent Developments and Future Plans
Figure 30. GlaxoSmithKline Recent Developments and Future Plans
Figure 31. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players in 2021
Figure 32. PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 33. Global Top 3 Players PD-1 and PD-L1 Immunotherapy Revenue Market Share in 2021
Figure 34. Global Top 10 Players PD-1 and PD-L1 Immunotherapy Revenue Market Share in 2021
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 36. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Type in 2021
Figure 37. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Type (2023-2028)
Figure 38. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application in 2021
Figure 39. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Application (2023-2028)
Figure 40. North America PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2017-2028)
Figure 41. North America PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2017-2028)
Figure 42. North America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 43. United States PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2017-2028)
Figure 47. Europe PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2017-2028)
Figure 48. Europe PD-1 and PD-L1 Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 49. Germany PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2017-2028)
Figure 55. Asia-Pacific PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific PD-1 and PD-L1 Immunotherapy Revenue Market Share by Region (2017-2028)
Figure 57. China PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. South Korea PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2017-2028)
Figure 64. South America PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2017-2028)
Figure 65. South America PD-1 and PD-L1 Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 66. Brazil PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales Market Share by Type (2017-2028)
Figure 69. Middle East and Africa PD-1 and PD-L1 Immunotherapy Sales Market Share by Application (2017-2028)
Figure 70. Middle East and Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share by Country (2017-2028)
Figure 71. Turkey PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Saudi Arabia PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. UAE PD-1 and PD-L1 Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source